Enalapril maleate/Hydrochlorothiazide: Difference between revisions
(Created page with "{|class="infobox" style="position: fixed; top: 180px; right: 20px; margin: 0 0 0 0; border: 0; float: right; width: 15%; background: #104E8B; border-radius: 10px 10px 10px 10p...") |
No edit summary |
||
Line 52: | Line 52: | ||
'''''For information about (Generic Name), click [[(Generic Name)|here]].''''' | '''''For information about (Generic Name), click [[(Generic Name)|here]].''''' | ||
{{SB}} | {{SB}} Vaseretic<sup>®</sup> | ||
==Disclaimer== | ==Disclaimer== | ||
Line 73: | Line 73: | ||
<font color="#F8F8FF" style="font-weight: bold;"> | <font color="#F8F8FF" style="font-weight: bold;"> | ||
''{{fontcolor|#FF0000|Condition Name:}}'' | ''{{fontcolor|#FF0000|Condition Name:}}'' * When pregnancy is detected, discontinue VASERETIC® as soon as possible. | ||
* Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See Warnings: Fetal Toxicity | |||
</font> | </font> | ||
|} | |} | ||
Line 79: | Line 80: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} is a | {{PAGENAME}} is a angiontensin converting enzyme inhibitor and [[thiazide diuretic]] drug that is FDA approved for the treatment of [[hypertension]] There is a Black Box Warning for this drug as shown <span style="background:#000000;">'''[[{{PAGENAME}}#Black Box Warning|{{fontcolor|#FF0000|here}}]]'''</span>. Common adverse reactions include [[dizziness]], [[headache]], [[fatigue]] and [[cough]]. | ||
==Adult Indications and Dosage== | ==Adult Indications and Dosage== | ||
=== | =====Hypertension===== | ||
* Dosing information | |||
* | :* Enalapril: '''10-40 mg PO qd or bid''' | ||
:* Hydrochlorothiazide: '''12.5-50 mg PO qd'''. | |||
===FDA-Labeled Indications and Dosage (Adult)=== | |||
=== | |||
==Pediatric Indications and Dosage== | ==Pediatric Indications and Dosage== | ||
==Contraindications== | ==Contraindications== | ||
VASERETIC is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of [[angioedema]] related to previous treatment with an [[angiotensin converting enzyme inhibitor]] and in patients with hereditary or [[idiopathic angioedema]]. Because of the [[hydrochlorothiazide]] component, this product is contraindicated in patients with [[anuria]] or [[hypersensitivity]] to other sulfonamide-derived drugs. | |||
Do not co-administer aliskiren with VASERETIC in patients with diabetes (see PRECAUTIONS, Drug Interactions). | |||
==Warnings== | ==Warnings== | ||
Revision as of 18:33, 5 May 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For information about (Generic Name), click here.
Synonyms / Brand Names: Vaseretic®
Disclaimer
WikiDoc Drug Project is a constellation of drug information for healthcare providers and patients vigorously vetted on the basis of FDA package insert, MedlinePlus, Practice Guidelines, Scientific Statements, and scholarly medical literature. The information provided is not a medical advice or treatment. WikiDoc does not promote any medication or off-label use of drugs. Please read our full disclaimer here.
Black Box Warning
FDA Package Insert for Enalapril maleate/Hydrochlorothiazide contains no information regarding Black Box Warning.
WARNING See full prescribing information for complete boxed warning. Condition Name: * When pregnancy is detected, discontinue VASERETIC® as soon as possible.
|
Overview
Enalapril maleate/Hydrochlorothiazide is a angiontensin converting enzyme inhibitor and thiazide diuretic drug that is FDA approved for the treatment of hypertension There is a Black Box Warning for this drug as shown here. Common adverse reactions include dizziness, headache, fatigue and cough.
Adult Indications and Dosage
Hypertension
- Dosing information
- Enalapril: 10-40 mg PO qd or bid
- Hydrochlorothiazide: 12.5-50 mg PO qd.
FDA-Labeled Indications and Dosage (Adult)
Pediatric Indications and Dosage
Contraindications
VASERETIC is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.
Do not co-administer aliskiren with VASERETIC in patients with diabetes (see PRECAUTIONS, Drug Interactions).
Warnings
Conidition 1
(Description)
Conidition 2
(Description)
Conidition 3
(Description)
Adverse Reactions
Clinical Trials Experience
Condition 1
Central Nervous System
- (list/description of adverse reactions)
Cardiovascular
- (list/description of adverse reactions)
Respiratory
- (list/description of adverse reactions)
Gastrointestinal
- (list/description of adverse reactions)
Hypersensitive Reactions
- (list/description of adverse reactions)
Miscellaneous
- (list/description of adverse reactions)
Condition 2
Central Nervous System
- (list/description of adverse reactions)
Cardiovascular
- (list/description of adverse reactions)
Respiratory
- (list/description of adverse reactions)
Gastrointestinal
- (list/description of adverse reactions)
Hypersensitive Reactions
- (list/description of adverse reactions)
Miscellaneous
- (list/description of adverse reactions)
Postmarketing Experience
(Description)
Drug Interactions
- Drug 1
- Drug 2
- Drug 3
- Drug 4
- Drug 5
Drug 1
(Description)
Drug 2
(Description)
Drug 3
(Description)
Drug 4
(Description)
Drug 5
(Description)
Use in Specific Populations
Pregnancy
- Pregnancy Category (AUS): Enalapril maleate/Hydrochlorothiazide is not included in Australian Drug Evaluation Committee (ADEC) Pregnancy Categories.
(Description)
Labor and Delivery
(Description)
Nursing Mothers
(Description)
Pediatric Use
(Description)
Geriatric Use
(Description)
Gender
(Description)
Race
(Description)
Renal Impairment
(Description)
Hepatic Impairment
(Description)
Carcinogenesis, Mutagenesis, Impairment of Fertility
(Description)
Immunocompromised Patients
(Description)
Miscellaneous
(Description)
Administration and Monitoring
Administration
(Oral/Intravenous/etc)
Monitoring
Condition 1
(Description regarding monitoring, from Warnings section)
Condition 2
(Description regarding monitoring, from Warnings section)
Condition 3
(Description regarding monitoring, from Warnings section)
IV Compatibility
Solution
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Y-Site
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Admixture
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Syringe
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
TPN/TNA
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Overdosage
Acute Overdose
Signs and Symptoms
(Description)
Management
(Description)
Chronic Overdose
Signs and Symptoms
(Description)
Management
(Description)
Pharmacology
Enalapril maleate/Hydrochlorothiazide
| |
Systematic (IUPAC) name | |
? | |
Identifiers | |
CAS number | ? |
ATC code | ? |
PubChem | ? |
Chemical data | |
Formula | ? |
Mol. mass | ? |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Mechanism of Action
(Description)
Structure
(Description with picture)
Pharmacodynamics
(Description)
Pharmacokinetics
(Description)
Nonclinical Toxicology
(Description)
Clinical Studies
Condition 1
(Description)
Condition 2
(Description)
Condition 3
(Description)
How Supplied
(Description)
- National Drug Code (NDC):
- Storage:
- Manufactured by:
- Distributed by:
Images
Drug Images
Package and Label Display Panel
(Package Images)
(Display Panel Images)
Patient Information
Patient Information from FDA
(Patient Counseling Information)
Patient Information from NLM
(Link to patient information page)
Precautions with Alcohol
Alcohol-Enalapril maleate/Hydrochlorothiazide interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
Brand Names®
Look-Alike Drug Names
- (Paired Confused Name 1a) — (Paired Confused Name 1b)
- (Paired Confused Name 2a) — (Paired Confused Name 2b)
- (Paired Confused Name 3a) — (Paired Confused Name 3b)